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Abstract 
The assessment of extranodal lymphomas poses 
considerable challenges to histopathologists in rutine 
work, because of the breadth of lymphoma subtypes, 
the variation in morphology, immunophenotype, 
genetics and clinical features of these entities, the 
difficulties in differential diagnosis, and the 
differential diagnosis, and the different clinical 
significance of lymphomas with primary versus 
secondary involvement of extranodal sites. DLBCL-
NOS is the more frequent extranodal lymphoma 
subtype, which has characteristic features. Here the 
clinicopathology of extranodal lymphomas will be 
discussed. 
Clinics and pathology 
Disease 
Proposed definitions of extranodal lymphoma vary, 
according to purpose, from lymphomas restricted to 
a single extranodal site and its regional lymph nodes 
to lymphomas which may be more widespread but in 
which an extranodal organ is the presenting and 
predominant site of disease, to which therapy may be 
primarily aimed. Extranodal lymphomas are 
different from those of lymph nodes, representing 
approximately 25-50% of all non-Hodgkin 
lymphomas (only 2-5% of classical Hodgkin 
lymphomas present at extranodal sites) (d'Amore et 
al. 2008.). Most lymphomas are from the 
gastrointestinal (GI) tract, followed by skin, 
Waldeyer's ring, central nervous system, salivary 
glands, orbit, lung, bone, sinonasal tract, thyroid 
gland, testes, breast and other sites. (d'Amore et al. 
2008; Heckendorn, et al. 2015. Siddiqui et al. 2009.) 
Both the lymphoma subtype and the organ involved 
may influence the clinical behaviour and 
management of the lymphoma. 
Both B- and T/NK-cell lymphomas can occur in 
extranodal sites, in which B-cell lymphoms are more 
common. At most of extranodal sites, DLBCL-NOS 
is the most frequent lymphoma subtype. Although 
sharing features typical of DLBC-NOS at any site of 
destructive tumours composed of diffuse sheets of 
large atypical B cells with prominent nucleoli and a 
high proliferative rate, DLBCL arising at some 
extranodal sites has characteristic features. For 
example, DLBCL of the testis and DLBCL of the 
central nervous system (DLBCL-CNS) share 
characteristic deletions of chromosome 6p21.3 
leading to loss of HLA genes, not seen in nodal 
DLBCL. Clinically, DLBCL-NOS of Waldeyer's 
ring and the GI tract have a better prognosis than 
DLBCL-NOS) overall, while testicular DLBCL-
NOS has a worse outcome with a tendency for spread 
or relapse to other extranodal sites, particularly the 
CNS, and a propensity for late relapse.(Bacon, et 
al.2009. Swerdlow et al, 2008. Swerdlow et al, 2016. 
) 
Phenotype/cell stem origin 
DLBCL-NOS arising at some extranodal sites has 
characteristic features, which arising in bone often 
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has multilobated nuclei, and those of the testis and 
stomach are usually of non-germinal centre 
immunophenotype while those of the small intestine 
and Waldeyer's ring are more often of germinal 
centre phenotype. DLBCL almost always expresses 
pan-B-cell markers, such as CD20. Most are bcl-6+, 
many are bcl-2+, and a minority are CD10+ 
(Swerdlow et al, 2008. Ferry 2008). 
Epidemiology 
DLBCL is the most common extranodal lymphoma, 
and it is the most common lymphoma encountered in 
GI, the central nervous system, the eyes, the 
paranasal sinuses, Waldeyer ring, bone, heart, 
adrenals, and other sites. DLBCL is mainly found in 
older adults, with a median age in the seventh 
decade, but younger adults and children are 
occasionally affected. There is a slight male 
preponderance overall, but this varies among 
anatomic sites (Swerdlow et al, 2008. Ferry 2008). 
Clinics 
Patients usually present with a rapidly enlarging 
tumor mass at single or multiple extranodal sites. 
DLBCL typically produces large, destructive lesions 
that may invade adjacent structures. Almost half of 
the patients have stage I or II disease. Most patients 
are asymptomatic but when symptoms are present 
they are highly dependent on the site of involement. 
Extranodal DLBCL-NOS is relatively increased in 
frequency in immunosuppressed individuals 
(Swerdlow et al, 2008. Ferry 2008. Bacon et al. 
2009). 
Pathology 
Microscopic examination reveals a diffuse 
proliferation of large cells with round, oval, 
irregular, or lobated nuclei, distinct nucleoli, and 
scant cytoplasm. In a few cases, neoplastic cells may 
be bizarre or anaplastic, and in occasional cases, they 
may show plasmacytoid differentiation. In some 
cases, there is a concomitant component of low-
grade lymphoma or a history of low-grade 
lymphoma (marginal zone lymphoma, follicular 
lymphoma, etc) consistent with large-cell 
transformation. 
 
Figure 1.  Primary DLBCL of the breast. Diffuse proliferation of lymphoid cells can be seen between ducts of 
the breast. Some ducts are distructed by the lymphoid cells, which are small to medium sized with sheets of large 
cells (HE staining). 
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Figure 2.  The lymphoid cells are large, with oval nuclei and distinct nucleoli. (HE staining). 
 
Figure3.  The cells are positive for CD20.
 
Treatment 
Both the lymphoma subtype and the organ involved 
may influence the clinical behaviour and 
management of the lymphoma. DLBCL are 
aggressive but potentially curable with multi-agent 
chemotherapy. The CHOP regimen has been the 
mainstay of therapy for several decades. The 
addition of the anti-CD20 monoclonal antibody 
rituximab to CHOP (R-CHOP) has led to a marked 
improvement in survival (Swerdlow et al,2008. 
Ferry, 2008. Bacon et al.2009). One study suggests  
 
that anatomical location in B-NHL is governed by 
the differential expression of specific 
adhesion/motility molecules and provides 
implications for therapeutic strategies that aim to 
disrupt protective micro-environmental interactions 
(Middle et al. 2015.). 
Prognosis 
Clinically, DLBCL of Waldeyer's ring and the GI 
tract have a better prognosis than DLBCL overall, 
while testicular DLBCL has a worse outcome with a 
tendency for spread or relapse to other extranodal 
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sites, particularly the CNS, and a propensity for late 
relapse (Swerdlow, et al, 2008. Bacon, et al. 2009). 
Cytogenetics 
Cytogenetics morphological 
There is emerging evidence of differences and 
similarities in somatic genetic abnormalities 
between DLBCL-NOS arising at different sites. For 
example, DLBCL-NOS of the testis and DLBCL-
CNS (both tumours of immune privileged sites) 
share characteristic deletions of chromosome 6p21.3 
leading to loss of HLA genes, not seen in nodal 
DLBCL (Swerdlow et al, 2008. Bacon et al. 2009). 
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